Amyloid formation in light chain amyloidosis

Current Topics in Medicinal Chemistry

Volumn 12, Issue 22, 2012, Pages 2523-2533

  Ramirez Alvarado, Marina ^a  

^a MAYO GRADUATE SCHOOL   (United States)

Author keywords

Amyloid formation; Dimer; Immunoglobulin light chain; Light chain amyloidosis; Somatic mutations

Indexed keywords

AMYLOID; GLYCOSAMINOGLYCAN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN LIGHT CHAIN; IMMUNOGLOBULIN M;

AMINO ACID SEQUENCE; AMYLOIDOSIS; ARTICLE; COMPLEMENTARITY DETERMINING REGION; CRYSTAL STRUCTURE; CYTOTOXICITY; DISEASE COURSE; DISEASE SEVERITY; ENVIRONMENTAL FACTOR; GERM LINE GENE THERAPY; GLYCOSYLATION; HUMAN; IMMUNOGLOBULIN STRUCTURE; INTERNALIZATION; KINETICS; MASS SPECTROMETRY; MUTATIONAL ANALYSIS; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PLASMA CELL; PROTEIN STABILITY; SOMATIC MUTATION; THERMODYNAMICS; TISSUE INJURY;

AMYLOID; AMYLOIDOSIS; ANIMALS; GLYCOSAMINOGLYCANS; HUMANS; IMMUNOGLOBULIN LIGHT CHAINS; MUTATION; THERMODYNAMICS;

EID: 84874869909     PISSN: 15680266     EISSN: 18734294     Source Type: Journal    
DOI: 10.2174/1568026611212220007     Document Type: Article

References (87)

1. Baden, E. M.; Sikkink, L. A.; Ramirez-Alvarado, M., Light chain amyloidosis - current findings and future prospects. Curr. Protein Pept. Sci., 2009, 10(5), 500-508.
2. DiCostanzo, A. C.; Ramirez-Alvarado, M., Current and New Perspectives on the Molecular and Cellular Mechanisms of Amyloid Formation and Toxicity in Light Chain Amyloidosis. InTech:, 2011; pp. 1-22.
3. Branden, C.; Tooze, J., Introduction to protein structure. 2nd ed.; Garland Publishing, Inc: New York, 1999; p. 410.
4. Poshusta, T. L.; Sikkink, L. A.; Leung, N.; Clark, R. J.; Dispenzieri, A.; Ramirez-Alvarado, M., Mutations in specific structural regions of immunoglobulin light chains are associated with free light chain levels in patients with AL amyloidosis. PLoS One, 2009, 4(4), e5169.
5. Kyle, R. A.; Gertz, M. A., Primary systemic amyloidosis: clinical and laboratory features in 474 cases. Semin Hematol, 1995, 32(1), 45-59.
6. Perfetti, V.; Casarini, S.; Palladini, G.; Vignarelli, M. C.; Klersy, C.; Diegoli, M.; Ascari, E.; Merlini, G., Analysis of V(lambda)-J(lambda) expression in plasma cells from primary (AL) amyloidosis and normal bone marrow identifies 3r (lambdaIII) as a new amyloid-associated germline gene segment. Blood, 2002, 100(3), 948-953.
7. Abraham, R. S.; Geyer, S. M.; Price-Troska, T. L.; Allmer, C.; Kyle, R. A.; Gertz, M. A.; Fonseca, R., Immunoglobulin light chain variable (V) region genes influence clinical presentation and outcome in light chain-associated amyloidosis (AL). Blood, 2003, 101(10), 3801-3808.
8. Comenzo, R. L.; Zhang, Y.; Martinez, C.; Osman, K.; Herrera, G. A., The tropism of organ involvement in primary systemic amyloidosis: contributions of Ig V(L) germ line gene use and clonal plasma cell burden. Blood, 2001, 98(3), 714-720.
9. Prokaeva, T.; Spencer, B.; Kaut, M.; Ozonoff, A.; Doros, G.; Connors, L. H.; Skinner, M.; Seldin, D. C., Soft tissue, joint, and bone manifestations of AL amyloidosis: clinical presentation, molecular features, and survival. Arthritis Rheum, 2007, 56(11), 3858-3868.
10. Perfetti, V.; Palladini, G.; Casarini, S.; Navazza, V.; Rognoni, P.; Obici, L.; Invernizzi, R.; Perlini, S.; Klersy, C.; Merlini, G., The repertoire of lambda light chains causing predominant amyloid heart involvement and identification of a preferentially involved germline gene, IGLV1-44. Blood, 2012, 119(1), 144-150.
11. Stevens, F. J., Four structural risk factors identify most fibrilforming kappa light chains. Amyloid, 2000, 7(3), 200-211.
12. Dispenzieri, A.; Zhang, L.; Katzmann, J. A.; Snyder, M.; Blood, E.; Degoey, R.; Henderson, K.; Kyle, R. A.; Oken, M. M.; Bradwell, A. R.; Greipp, P. R., Appraisal of immunoglobulin free light chain as a marker of response. Blood, 2008, 111(10), 4908-4915.
13. Hurle, M. R.; Helms, L. R.; Li, L.; Chan, W.; Wetzel, R., A role for destabilizing amino acid replacements in light-chain amyloidosis. Proc Natl Acad Sci U S A, 1994, 91(12), 5446-5450.
14. Stevens, P. W.; Raffen, R.; Hanson, D. K.; Deng, Y.-L.; Berrios-Hammond, M.; Westholm, F. A.; Murphy, C.; Eulitz, M.; Wetzel, R.; Solomon, A.; Schiffer, M.; Stevens, F. J., Recombinant immunoglobulin variable domains generated from synthetic genes provide a system for in vitro characterization of light-chain amyloid proteins. Protein Sci, 1995, 4, 421-432.
15. Wetzel, R., Domain stability in immunoglobulin light chain deposition disorders. Adv Protein Chem, 1997, 50, 183-242.
16. Kim, Y.; Wall, J. S.; Meyer, J.; Murphy, C.; Randolph, T. W.; Manning, M. C.; Solomon, A.; Carpenter, J. F., Thermodynamic modulation of light chain amyloid fibril formation. J Biol Chem, 2000, 275(3), 1570-1574.
17. Wall, J.; Schell, M.; Murphy, C.; Hrncic, R.; Stevens, F. J.; Solomon, A., Thermodynamic instability of human lambda 6 light chains: correlation with fibrillogenicity. Biochemistry, 1999, 38(42), 14101-14108.
18. Baden, E. M.; Randles, E. G.; Aboagye, A. K.; Thompson, J. R.; Ramirez-Alvarado, M., Structural insights into the role of mutations in amyloidogenesis. J Biol Chem, 2008, 283(45), 30950-30956.
19. Baden, E. M.; Owen, B. A.; Peterson, F. C.; Volkman, B. F.; Ramirez-Alvarado, M.; Thompson, J. R., Altered dimer interface decreases stability in an amyloidogenic protein. J Biol Chem, 2008, 283(23), 15853-15860.
20. Del Pozo Yauner, L.; Ortiz, E.; Sanchez, R.; Sanchez-Lopez, R.; Guereca, L.; Murphy, C. L.; Allen, A.; Wall, J. S.; Fernandez-Velasco, D. A.; Solomon, A.; Becerril, B., Influence of the germline sequence on the thermodynamic stability and fibrillogenicity of human lambda 6 light chains. Proteins, 2008, 72(2), 684-692.
21. Davis, P. D.; Raffen, R.; Dul, L. J.; Vogen, M. S.; Williamson, K. E.; Stevens, J. F.; Argon, Y., Inhibition of amyloid fiber assembly by both BiP and its target peptide. Immunity, 2000, 13(4), 433-442.
22. Martin, D. J.; Ramirez-Alvarado, M., Comparison of amyloid fibril formation by two closely related immunoglobulin light chain variable domains. Amyloid, 2010, 17(3-4), 129-136.
23. Ionescu-Zanetti, C.; Khurana, R.; Gillespie, J. R.; Petrick, J. S.; Trabachino, L. C.; Minert, L. J.; Carter, S. A.; Fink, A. L., Monitoring the assembly of Ig light-chain amyloid fibrils by atomic force microscopy. Proc Natl Acad Sci U S A, 1999, 96(23), 13175-13179.
24. Khurana, R.; Gillespie, J. R.; Talapatra, A.; Minert, L. J.; Ionescu-Zanetti, C.; Millett, I.; Fink, A. L., Partially folded intermediates as critical precursors of light chain amyloid fibrils and amorphous aggregates. Biochemistry, 2001, 40(12), 3525-3535.
25. Souillac, P. O.; Uversky, V. N.; Fink, A. L., Structural transformations of oligomeric intermediates in the fibrillation of immunoglobulin light chain LEN. Biochemistry, 2003, 42, (26), 8094-8104.
26. Souillac, P. O.; Uversky, V. N.; Millett, I. S.; Khurana, R.; Doniach, S.; Fink, A. L., Elucidation of the molecular mechanism during the early events in immunoglobulin light chain amyloid fibrillation. Evidence for an off- pathway oligomer at acidic pH. J Biol Chem, 2002, 277(15), 12666-12679.
27. Souillac, P. O.; Uversky, V. N.; Millett, I. S.; Khurana, R.; Doniach, S.; Fink, A. L., Effect of association state and conformational stability on the kinetics of immunoglobulin light chain amyloid fibril formation at physiological pH. J Biol Chem, 2002, 277(15), 12657-12665.
28. Ch'ang, L. Y.; Yen, C. P.; Besl, L.; Schell, M.; Solomon, A., Identification and characterization of a functional human Ig V lambda VI germline gene. Mol Immunol, 1994, 31(7), 531-536.
29. del Pozo Yauner, L.; Ortiz, E.; Becerril, B., The CDR1 of the human lambdaVI light chains adopts a new canonical structure. Proteins, 2006, 62(1), 122-129.
30. Wall, J. S.; Gupta, V.; Wilkerson, M.; Schell, M.; Loris, R.; Adams, P.; Solomon, A.; Stevens, F.; Dealwis, C., Structural basis of light chain amyloidogenicity: comparison of the thermodynamic properties, fibrillogenic potential and tertiary structural features of four Vlambda6 proteins. J Mol Recognit, 2004, 17(4), 323-331.
31. Schroeder, H. W., Jr.; Cavacini, L., Structure and function of immunoglobulins. J Allergy Clin Immunol, 2010, 125(2 Suppl 2), S41-S52.
32. Olsen, K. E.; Sletten, K.; Westermark, P., Fragments of the constant region of immunoglobulin light chains are constituents of ALamyloid proteins. Biochem Biophys Res Commun, 1998, 251(2), 642-647.
33. Lavatelli, F.; Perlman, D. H.; Spencer, B.; Prokaeva, T.; McComb, M. E.; Theberge, R.; Connors, L. H.; Bellotti, V.; Seldin, D. C.; Merlini, G.; Skinner, M.; Costello, C. E., Amyloidogenic and associated proteins in systemic amyloidosis proteome of adipose tissue. Mol Cell Proteomics, 2008, 7(8), 1570-1583.
34. Vrana, J. A.; Gamez, J. D.; Madden, B. J.; Theis, J. D.; Bergen, H. R., 3rd; Dogan, A., Classification of amyloidosis by laser microdissection and mass spectrometry-based proteomic analysis in clinical biopsy specimens. Blood, 2009, 114(24), 4957-4959.
35. Klimtchuk, E. S.; Gursky, O.; Patel, R. S.; Laporte, K. L.; Connors, L. H.; Skinner, M.; Seldin, D. C., The critical role of the constant region in thermal stability and aggregation of amyloidogenic immunoglobulin light chain. Biochemistry, 2010, 49(45), 9848-9857
36. Alim, M. A.; Yamaki, S.; Hossain, M. S.; Takeda, K.; Kozima, M.; Izumi, T.; Takashi, I.; Shinoda, T., Structural relationship of kappatype light chains with AL amyloidosis: multiple deletions found in a VkappaIV protein. Clin Exp Immunol, 1999, 118(3), 344-348.
37. Bourne, P. C.; Ramsland, P. A.; Shan, L.; Fan, Z. C.; DeWitt, C. R.; Shultz, B. B.; Terzyan, S. S.; Moomaw, C. R.; Slaughter, C. A.; Guddat, L. W.; Edmundson, A. B., Three-dimensional structure of an immunoglobulin light-chain dimer with amyloidogenic properties. Acta Crystallogr D Biol Crystallogr, 2002, 58(Pt 5), 815-823.
38. Epp, O.; Lattman, E. E.; Schiffer, M.; Huber, R.; Palm, W., The molecular structure of a dimer composed of the variable portions of the Bence-Jones protein REI refined at 2.0-A resolution. Biochemistry, 1975, 14(22), 4943-4952.
39. Huang, D. B.; Chang, C. H.; Ainsworth, C.; Brunger, A. T.; Eulitz, M.; Solomon, A.; Stevens, F. J.; Schiffer, M., Comparison of crystal structures of two homologous proteins: structural origin of altered domain interactions in immunoglobulin light-chain dimers. Biochemistry, 1994, 33(49), 14848-14857.
40. Pokkuluri, P. R.; Solomon, A.; Weiss, D. T.; Stevens, F. J.; Schiffer, M., Tertiary structure of human lambda 6 light chains. Amyloid, 1999, 6(3), 165-171.
41. Schormann, N.; Murrell, J. R.; Liepnieks, J. J.; Benson, M. D., Tertiary structure of an amyloid immunoglobulin light chain protein: a proposed model for amyloid fibril formation. Proc Natl Acad Sci U S A, 1995, 92(21), 9490-9494.
42. Hernandez-Santoyo, A.; del Pozo Yauner, L.; Fuentes-Silva, D.; Ortiz, E.; Rudino-Pinera, E.; Sanchez-Lopez, R.; Horjales, E.; Becerril, B.; Rodriguez-Romero, A., A single mutation at the sheet switch region results in conformational changes favoring lambda6 light-chain fibrillogenesis. J Mol Biol, 2010, 396(2), 280-292.
43. Peterson, F. C.; Baden, E. M.; Owen, B. A.; Volkman, B. F.; Ramirez- Alvarado, M., A single mutation promotes amyloidogenicity through a highly promiscuous dimer interface. Structure, 2010, 18(5), 563-570.
44. Chiti, F.; Webster, P.; Taddei, N.; Clark, A.; Stefani, M.; Ramponi, G.; Dobson, C. M., Designing conditions for in vitro formation of amyloid protofilaments and fibrils. Proc Natl Acad Sci U S A, 1999, 96(7), 3590-3594.
45. Khurana, R.; Souillac, P. O.; Coats, A. C.; Minert, L. J.; Ionescu-Zanetti, C.; Carter, S. A.; Solomon, A.; Fink, A. L., A model for amyloid formation in immunoglobulin light chains based on comparison of amyloidogenic and benign proteins and specific antibody binding. Amyloid, 2003, 10, 97-109.
46. Zhu, M.; Han, S.; Zhou, F.; Carter, S. A.; Fink, A. L., Annular oligomeric amyloid intermediates observed by in situ atomic force microscopy. J Biol Chem, 2004, 279(23), 24452-24459.
47. Kim, Y. S.; Cape, S. P.; Chi, E.; Raffen, R.; Wilkins-Stevens, P.; Stevens, F. J.; Manning, M. C.; Randolph, T. W.; Solomon, A.; Carpenter, J. F., Counteracting effects of renal solutes on amyloid fibril formation by immunoglobulin light chains. J Biol Chem, 2001, 276(2), 1626-1633.
48. Qin, Z.; Hu, D.; Zhu, M.; Fink, A. L., Structural characterization of the partially folded intermediates of an immunoglobulin light chain leading to amyloid fibrillation and amorphous aggregation. Biochemistry, 2007, 46(11), 3521-3531.
49. Powers, E. T.; Powers, D. L., Mechanisms of protein fibril formation: nucleated polymerization with competing off-pathway aggregation. Biophys J, 2008, 94(2), 379-391.
50. Harper, J. D.; Lansbury, P. T., Jr., Models of amyloid seeding in Alzheimer's disease and scrapie: mechanistic truths and physiological consequences of the time-dependent solubility of amyloid proteins. Annu Rev Biochem, 1997, 66, 385-407.
51. Martin, D. J.; Ramirez-Alvarado, M., Glycosaminoglycans promote fibril formation by amyloidogenic immunoglobulin light chains through a transient interaction. Biophys Chem, 2011, 158(1), 81-89.
52. Zhu, M.; Souillac, P. O.; Ionescu-Zanetti, C.; Carter, S. A.; Fink, A. L., Surface-catalyzed amyloid fibril formation. J Biol Chem, 2002, 277(52), 50914-50922.
53. Wall, J. S.; Ayoub, F. M.; O'Shea, P. S., A study of the interactions of an immunoglobulin light chain with artificial and B-lymphocyte membranes. Front Biosci, 1996, 1, a46-a58.
54. Meng, X.; Fink, A. L.; Uversky, V. N., The effect of membranes on the in vitro fibrillation of an amyloidogenic light-chain variabledomain SMA. J Mol Biol, 2008, 381(4), 989-999.
55. Bosman, F. T.; Stamenkovic, I., Functional structure and composition of the extracellular matrix. J Pathol, 2003, 200(4), 423-428.
56. Ohishi, H.; Skinner, M.; Sato-Araki, N.; Okuyama, T.; Gejyo, F.; Kimura, A.; Cohen, A. S.; Schmid, K., Glycosaminoglycans of the hemodialysis-associated carpal synovial amyloid and of amyloidrich tissues and fibrils of heart, liver, and spleen. Clin Chem, 1990, 36(1), 88-91.
57. Jiang, X.; Myatt, E.; Lykos, P.; Stevens, F. J., Interaction between glycosaminoglycans and immunoglobulin light chains. Biochemistry, 1997, 36(43), 13187-13194.
58. Keeling, J.; Teng, J.; Herrera, G. A., AL-amyloidosis and lightchain deposition disease light chains induce divergent phenotypic transformations of human mesangial cells. Lab Invest, 2004, 84(10), 1322-1338.
59. Trinkaus-Randall, V.; Walsh, M. T.; Steeves, S.; Monis, G.; Connors, L. H.; Skinner, M., Cellular response of cardiac fibroblasts to amyloidogenic light chains. Am J Pathol, 2005, 166(1), 197-208.
60. McLaughlin, R. W.; De Stigter, J. K.; Sikkink, L. A.; Baden, E. M.; Ramirez-Alvarado, M., The effects of sodium sulfate, glycosaminoglycans, and Congo red on the structure, stability, and amyloid formation of an immunoglobulin light-chain protein. Protein Sci, 2006, 15(7), 1710-1722.
61. Ren, R.; Hong, Z.; Gong, H.; Laporte, K.; Skinner, M.; Seldin, D. C.; Costello, C. E.; Connors, L. H.; Trinkaus-Randall, V., Role of glycosaminoglycan sulfation in the formation of immunoglobulin light chain amyloid oligomers and fibrils. J Biol Chem, 2011, 285(48), 37672-37682.
62. Cacace, M. G.; Landau, E. M.; Ramsden, J. J., The Hofmeister series: salt and solvent effects on interfacial phenomena. Q Rev Biophys, 1997, 30(3), 241-277.
63. Zhang, Y.; Furyk, S.; Bergbreiter, D. E.; Cremer, P. S., Specific ion effects on the water solubility of macromolecules: PNIPAM and the Hofmeister series. J Am Chem Soc, 2005, 127(41), 14505-14510.
64. Sikkink, L. A.; Ramirez-Alvarado, M., Salts enhance both protein stability and amyloid formation of an immunoglobulin light chain. Biophys Chem, 2008, 135(1/3), 25-31.
65. Shi, J.; Guan, J.; Jiang, B.; Brenner, D. A.; Del Monte, F.; Ward, J. E.; Connors, L. H.; Sawyer, D. B.; Semigran, M. J.; Macgillivray, T. E.; Seldin, D. C.; Falk, R.; Liao, R., Amyloidogenic light chains induce cardiomyocyte contractile dysfunction and apoptosis via a non-canonical p38alpha MAPK pathway. Proc Natl Acad Sci U S A, 2010, 107(9), 4188-4193.
66. Sikkink, L. A.; Ramirez-Alvarado, M., Cytotoxicity of amyloidogenic immunoglobulin light chains in cell culture. Cell Death and Disease, 2010, 1, e98.
67. Teng, J.; Russell, W. J.; Gu, X.; Cardelli, J.; Jones, M. L.; Herrera, G. A., Different types of glomerulopathic light chains interact with mesangial cells using a common receptor but exhibit different intracellular trafficking patterns. Lab Invest, 2004, 84(4), 440-451.
68. Monis, G. F.; Schultz, C.; Ren, R.; Eberhard, J.; Costello, C.; Connors, L.; Skinner, M.; Trinkaus-Randall, V., Role of endocytic inhibitory drugs on internalization of amyloidogenic light chains by cardiac fibroblasts. Am J Pathol, 2006, 169(6), 1939-1952.
69. Bateman, D. A.; Chakrabartty, A., Cell surface binding and internalization of abeta modulated by degree of aggregation. Int J Alzheimers Dis, 2011, 2011, 962352
70. Hartley, D. M.; Walsh, D. M.; Ye, C. P.; Diehl, T.; Vasquez, S.; Vassilev, P. M.; Teplow, D. B.; Selkoe, D. J., Protofibrillar intermediates of amyloid beta-protein induce acute electrophysiological changes and progressive neurotoxicity in cortical neurons. J Neurosci, 1999, 19(20), 8876-8884.
71. Reixach, N.; Deechongkit, S.; Jiang, X.; Kelly, J. W.; Buxbaum, J. N., Tissue damage in the amyloidoses: Transthyretin monomers and nonnative oligomers are the major cytotoxic species in tissue culture. Proc Natl Acad Sci U S A, 2004, 101(9), 2817-2822.
72. Berghoff, M.; Kathpal, M.; Khan, F.; Skinner, M.; Falk, R.; Freeman, R., Endothelial dysfunction precedes C-fiber abnormalities in primary (AL) amyloidosis. Ann Neurol, 2003, 53(6), 725-730.
73. Wittich, C. M.; Neben-Wittich, M. A.; Mueller, P. S.; Gertz, M. A.; Edwards, W. D., Deposition of amyloid proteins in the epicardial coronary arteries of 58 patients with primary systemic amyloidosis. Cardiovasc Pathol, 2007, 16(2), 75-78.
74. Neben-Wittich, M. A.; Wittich, C. M.; Mueller, P. S.; Larson, D. R.; Gertz, M. A.; Edwards, W. D., Obstructive intramural coronary amyloidosis and myocardial ischemia are common in primary amyloidosis. Am J Med, 2005, 118(11), 1287.
75. Migrino, R. Q.; Hari, P.; Gutterman, D. D.; Bright, M.; Truran, S.; Schlundt, B.; Phillips, S. A., Systemic and microvascular oxidative stress induced by light chain amyloidosis. Int J Cardiol, 2010, 145(1), 67-68.
76. Migrino, R. Q.; Truran, S.; Gutterman, D. D.; Franco, D. A.; Bright, M.; Schlundt, B.; Timmons, M.; Motta, A.; Phillips, S. A.; Hari, P., Human microvascular dysfunction and apoptotic injury induced by AL amyloidosis light chain proteins. Am J Physiol Heart Circ Physiol, 2011, 301(6), H2305-H2312.
77. Arendt, B. K.; Ramirez-Alvarado, M.; Sikkink, L. A.; Keats, J. J.; Ahmann, G. J.; Dispenzieri, A.; Fonseca, R.; Ketterling, R. P.; Knudson, R. A.; Mulvihill, E. M.; Tschumper, R. C.; Wu, X.; Zeldenrust, S. R.; Jelinek, D. F., Biologic and genetic characterization of the novel amyloidogenic lambda light chain-secreting human cell lines, ALMC-1 and ALMC-2. Blood, 2008, 112(5), 1931-1941.
78. Sikkink, L. A.; Ramirez-Alvarado, M., Biochemical and aggregation analysis of Bence Jones proteins from different light chain diseases. Amyloid, 2008, 15(1), 29-39.
79. Hrncic, R.; Wall, J.; Wolfenbarger, D. A.; Murphy, C. L.; Schell, M.; Weiss, D. T.; Solomon, A., Antibody-mediated resolution of light chain-associated amyloid deposits. Am J Pathol, 2000, 157(4), 1239-1246.
80. Ward, J. E.; Ren, R.; Toraldo, G.; Soohoo, P.; Guan, J.; O'Hara, C.; Jasuja, R.; Trinkaus-Randall, V.; Liao, R.; Connors, L. H.; Seldin, D. C., Doxycycline reduces fibril formation in a transgenic mouse model of AL amyloidosis. Blood, 2011, 118(25), 6610-6617.
81. Buxbaum, J. N., Animal models of human amyloidoses: are transgenic mice worth the time and trouble? FEBS Lett, 2009, 583(16), 2663-2673.
82. Sipe, J. D.; Cohen, A. S., Review: history of the amyloid fibril. J Struct Biol, 2000, 130(2-3), 88-98.
83. Kim, Y. S.; Randolph, T. W.; Manning, M. C.; Stevens, F. J.; Carpenter, J. F., Congo red populates partially unfolded states of an amyloidogenic protein to enhance aggregation and amyloid fibril formation. J Biol Chem, 2003, 278(12), 10842-10850.
84. O'Nuallain, B.; Allen, A.; Kennel, S. J.; Weiss, D. T.; Solomon, A.; Wall, J. S., Localization of a conformational epitope common to non-native and fibrillar immunoglobulin light chains. Biochemistry, 2007, 46(5), 1240-1247.
85. Solomon, A.; Weiss, D. T.; Wall, J. S., Immunotherapy in systemic primary (AL) amyloidosis using amyloid-reactive monoclonal antibodies. Cancer Biother Radiopharm, 2003, 18(6), 853-860.
86. Phipps, J. E.; Kestler, D. P.; Foster, J. S.; Kennel, S. J.; Donnell, R.; Weiss, D. T.; Solomon, A.; Wall, J. S., Inhibition of pathologic immunoglobulin-free light chain production by small interfering RNA molecules. Exp Hematol, 2010, 38(11), 1006-1013.
87. Hovey, B. M.; Ward, J. E.; Soo Hoo, P.; O'Hara, C. J.; Connors, L. H.; Seldin, D. C., Preclinical development of siRNA therapeutics for AL amyloidosis. Gene Ther, 2011, 18(12), 1150-1156.